Literature DB >> 21303450

Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases.

H von Euler1, S Eriksson.   

Abstract

As cell proliferation is one of the hallmarks of cancer, various types of proliferation markers are used as important tools in diagnosis, prognosis, treatment decision-making and follow-up in clinical oncology. The S phase-specific protein thymidine kinase 1 (TK1) can be used in immunohistochemistry for RNA/protein expression in tissue specimens and for activity or protein/peptide levels in serum from patients. TK1 has been used mainly in haematologic malignancies in humans, but also found beneficial in canine malignancies. As the protein sequence homology is high between humans and dogs, findings in canine models will have a high comparative value in further human research as well. In the present review, we will focus on the recent results concerning TK1's S phase-correlated expression, increased serum levels of TK1 in patients with malignancies and the relevance for veterinary and comparative oncology. Finally, the benefit of recently developed specific anti-TK1 antibodies suitable for immunologic assay is discussed.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21303450     DOI: 10.1111/j.1476-5829.2010.00238.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  10 in total

Review 1.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

2.  Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1.

Authors:  Z G Gulzar; J K McKenney; J D Brooks
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

3.  Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.

Authors:  Kiran Kumar Jagarlamudi; Sara Westberg; Henrik Rönnberg; Staffan Eriksson
Journal:  BMC Vet Res       Date:  2014-10-08       Impact factor: 2.741

4.  Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion.

Authors:  Tian Tian; Jun Li; Wenjun Hu; Cuiling Sun; Jian Zhou
Journal:  J Clin Lab Anal       Date:  2019-04-15       Impact factor: 2.352

5.  Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non-Hodgkin lymphoma.

Authors:  Pierre Boyé; Franck Floch; François Serres; Kévyn Geeraert; Pierre Clerson; Xavier Siomboing; Mattias Bergqvist; Gabriel Sack; Dominique Tierny
Journal:  J Vet Intern Med       Date:  2019-05-25       Impact factor: 3.333

6.  Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma.

Authors:  Liya Wang; Lucia Unger; Hanan Sharif; Staffan Eriksson; Vinzenz Gerber; Henrik Rönnberg
Journal:  BMC Mol Cell Biol       Date:  2021-12-14

7.  A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.

Authors:  Kiran Kumar Jagarlamudi; Laura Moreau; Sara Westberg; Henrik Rönnberg; Staffan Eriksson
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

8.  A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.

Authors:  J Kiran Kumar; A C Aronsson; G Pilko; M Zupan; K Kumer; T Fabjan; J Osredkar; S Eriksson
Journal:  Tumour Biol       Date:  2016-04-14

9.  Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.

Authors:  K A Selting; R Ringold; B Husbands; P O Pithua
Journal:  J Vet Intern Med       Date:  2016-05-23       Impact factor: 3.333

10.  Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells.

Authors:  Chang Liu; Jian Wang; Li Zhao; Hui He; Pan Zhao; Zheng Peng; Feiyuan Liu; Juan Chen; Weiqing Wu; Guangsuo Wang; Fajin Dong
Journal:  Front Oncol       Date:  2020-01-29       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.